Language:
Instant News and Commentaries
2025-07-25
04:36
Tesla’s Digital Assets Swell 72% Last Quarter, Misses Billions of USD by Early Bitcoin Sale

Tesla (TSLA.US) announced its quarterly results on Wednesday, revealing that its digital asset holdings have spiked by 72% from US$722 million in the same period last year to US$1.24 billion, reflecting the uptick in Bitcoin prices boosting asset value.

The market is watching whether Tesla will increase its Bitcoin holdings again to capitalize on the market uptrend, but the company has not disclosed any further cryptocurrency investment strategies.

However, Tesla purchased US$1.5 billion in Bitcoin in 2021 but sold about three-quarters of its holdings when the market plummeted the following year.

Subsequently, Bitcoin rebounded sharply, swelling approximately 80% over the past year, and Tesla missed out on potential gains of billions of US dollars.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
04:08
DJIA Concludes Down 316Pts as Tesla & IBM Sag ~8% Post-Earnings

The market was watchful of changes in trade agreements and quarterly corporate earnings, leading to mixed developments in US stocks on Thursday.

The S&P 500 closed up by 4 points at 6,363; and the Nasdaq rose by 37 points or 0.2% to 21,057, both setting new closing highs. However, the DJIA concluded down by 316 points or 0.7% at 44,693, dented by plunges in IBM (IBM.US) and Tesla (TSLA.US).

Tesla's 2Q earnings missed forecast with automotive revenue down 16%, whereas Elon Musk warned of challenging times ahead in the coming quarters, resulting in an 8.2% slump in its stock price for the day.

IBM (IBM.US) logged a 20% upswing in earnings, topping expectations, but its software gross margin was slightly lower, leading to a 7.6% drop in its stock price.

Alphabet (GOOG.US) reported a 19% hike in 2Q earnings, beating expectations, and raised its full-year capex, with its stock price initially soaring nearly 4% before closing with a gain of 0.9%.

Major techs were in a mixed bag, with Nvidia (NVDA.US) and Amazon (AMZN.US) both adding 1.7%, and Apple (AAPL.US) dipping 0.2%.
~



AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
02:51
Microsoft Sacks 15,000+ Jobs YTD

Microsoft (MSFT.US) CEO Satya Nadella informed employees on Thursday that the company has laid off more than 15,000 employees so far this year, describing the layoffs as very stressful for him.

Security, quality, and AI transformation are the three business priorities of the group, he added, and that they are working to lay a solid foundation while incessantly exploring new areas in AI.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
01:40
Apple Introduces iOS 26 Public Beta Version Featuring New Liquid Glass Interface

Apple (AAPL.US) officially launched the iOS 26 public beta version on Thursday, allowing global users to experience the next-generation iPhone operating system, which will be officially released this fall.

iOS 26 adopts a new liquid glass design style, replacing traditional buttons and menus with a semi-transparent look and adding smooth animation effects to simulate the texture of flowing glass, enhancing the overall visual experience.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
2025-07-24
09:14
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by the company. The trial is investigating ivonescimab in combination with chemotherapy, with or without ligufalimab (CD47 monoclonal antibody), for the first-line treatment of metastatic pancreatic cancer.

Pancreatic cancer remains one of the most challenging types of tumors to find effective treatments for. While immunotherapies have demonstrated significant efficacy in different types of of solid tumors, pancreatic cancer's unique immune evasion mechanisms and its highly immunosuppressive tumor microenvironment (TME) have rendered it resistant to current therapies. As a result, previous Phase III studies on using immunotherapies as first-line treatments for metastatic pancreatic cancer have mostly failed. To date, no immunotherapy has been approved for first line metastatic pancreatic cancer.

Ivonescimab, in combination with chemotherapy and/or ligufalimab, has the potential to address the current lack of effective options in first-line immunotherapy for metastatic pancreatic cancer. This randomized, controlled, multi-center Phase III trial is a key component of Akeso's broader strategy to address the significant unmet clinical needs in global oncology.

Pancreatic cancer is an extremely aggressive form of malignancy that often result in poor patient prognosis. Its global incidence is on the rise, and the mortality rate closely mirrors the incidence, resulting in alarmingly low overall survival rates. In 2022, approximately 511,000 new cases of pancreatic cancer were diagnosed worldwide, and 467,000 deaths were recorded. Early diagnosis remains challenging, with around 80% of patients being diagnosed at an advanced stage. Even those diagnosed with early-stage or locally advanced disease may see progression to metastatic pancreatic cancer within a year following surgery or other treatments. Current first-line treatments are predominantly chemotherapies and have showed very limited success, with a median overall survival (OS) of less than one year.

PD-1 and VEGF are often co-expressed in the tumor microenvironment. As a PD-1/VEGF bispecific antibody, Ivonescimab can accumulate in the TME and effectively block both the PD-1 and the VEGF signaling pathways. While these pathways are independently active, they are also complementary.  Inhibition of both PD-1 and VEGF enhances immune cells' ability to target and destroy tumor cells. In addition, ligufalimab binds to CD47 on tumor cells, disrupting the interaction with signal regulatory protein alpha (SIRPα) on phagocytic cells. This process boosts phagocytosis and inhibits tumor growth. The combination of ivonescimab with ligufalimab is expected to synergistically enhance anti-tumor activity, offering a potential breakthrough in the first-line treatment for metastatic pancreatic cancer.

Professor Yu Xianjun, Director of Fudan University Shanghai Cancer Center, Professor Ying Jie'er from Zhejiang Cancer Hospital, and Professor Tai Sheng from Harbin Medical University Cancer Hospital are the co-principal investigators of HARMONi-GI2 study.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

 

Information Provided by PR Newswire [Disclaimer]
08:50
Trump Once Mulls Nvidia Ring-fence

US President Donald Trump stated that he had considered splitting Nvidia (NVDA.US) to enhance competition in the AI chip sector, but later found that executing such a move in this industry is not easy.

Before understanding the situation, Trump had hoped to demerge Nvidia, but was informed by aides that doing so would be very difficult, Trump mentioned, adding that Nvidia holds a major advantage over all its competitors, which would take years to overcome.
~


AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
08:34
AMD: TSMC U.S. Plant Production Costs 5-20% Higher

AMD (AMD.US) CEO Lisa Su stated that chips produced by supplier TSMC's (TSM.US) Arizona plant incur higher costs compared to similar chips produced at their Taiwan plant. The cost of U.S. chips will be more than 5% higher but will not exceed 20%.

Su mentioned that AMD expects to produce its first batch of chips at TSMC's Arizona plant by the end of this year, considering the additional expenditure worthwhile as the company is achieving critical chip supply diversification. The aim is for the industry to be less prone to disruptions like those experienced during the pandemic.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
08:14
Tesla Tumbles 4%+ After Hours; Musk Warns of Tough Quarters Ahead

Tesla (TSLA.US) founder Elon Musk has warned that Tesla may face challenging conditions in the coming quarters as its core automotive business may take the hit from the end of electric vehicle subsidies.

Tesla's 2Q25 revenue fell by 12% to USD22.5 billion, marking the largest drop in at least a decade. Its adjusted EPS of USD0.4 were also shy of analysts' average expectations.

Tesla's stock price tumbled by 4.44% after hours to USD317.8.
~



AAStocks Financial News
Web Site: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
07:28
CN NEV-PV Retail Sales Slump 12% MoM in First 3 Wks of Jul: CPCA

In the first 20 days of July, China's national passenger vehicle (PV) market retailed 978,000 vehicles, up 11% YoY but down 12% MoM, according to data released by the China Passenger Car Association (CPCA). The YTD cumulative retail sales have grown 11% YoY to 11.88 million vehicles.

Meanwhile, the national new energy passenger vehicle (NEV-PV) market retailed 537,000 vehicles during this period, up 23% YoY but down 12% MoM.
~



AAStocks Financial News
Web Site: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
04:05
DJIA Advances 507 Pts w/ S&P 500 Hitting Another Closing High; Nvidia Gains 2%

US stocks rallied across the board on reports saying that the EU and the US were close to reaching an agreement to impose a 15% tariff on most products.

The DJIA rose 507 points or 1.1% throughout the day to a peak of 45,016, not far from its historical peak. The Nasdaq closed at 21,020, up 127 points or 0.6%, the first time it has ended the day above 21,000. The S&P 500 grew 49 points or 0.8% to close at 6,358, marking the 12th new high of the year.

Major tech stocks were mixed. Nvidia (NVDA.US) advanced over 2% at close. Meta (META.US) added 1%. Tesla (TSLA.US) edged up 0.1%. Alphabet (GOOG.US) and Apple (AAPL.US) inched 0.3% and 0.1% lower.
~



AAStocks Financial News
Web Site: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
Subscribe Newsletter
Get the latest news from us by inputing your email address here.
(Please read our Privacy Policy)